Boston Scientific Securities Fraud Lawsuit
Analysis based on 10 articles · First reported Feb 06, 2026 · Last updated Mar 11, 2026
The market was negatively impacted by Boston Scientific's disappointing financial results and subsequent stock price drop. The ongoing securities fraud lawsuit adds further uncertainty and negative sentiment towards Boston Scientific.
Boston Scientific reported disappointing fourth quarter and full year 2025 results, including lower-than-expected U.S. Electrophysiology sales and fiscal 2026 guidance. The company attributed this to slower market growth and increased competition, despite prior optimistic statements. Following this news, Boston Scientific's stock price fell by 17.6%. Consequently, the Law Offices of Howard G. Smith filed a securities fraud class action lawsuit against Boston Scientific, alleging that the company made materially false and misleading statements regarding its U.S. EP segment's growth trajectory and competitive landscape. Investors who purchased Boston Scientific securities during the Class Period (July 23, 2025, to February 3, 2026) are encouraged to participate in the lawsuit.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard